Trial Profile
A Phase II Study of MEDI4736 for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung-Map Sub-Study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 29 May 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Docetaxel
- Indications Lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Lung- Map Sub-Study
- 01 Dec 2021 Status changed from active, no longer recruiting to completed.
- 31 Jan 2021 Results (n=320) of an analysis assessing Tumor Mutation Burden and related biomarkers by NGS and determining associations with clinical outcomes using data from two clinical sub-studies: S1400I and S1400A presented at the 2020 World Conference on Lung Cancer
- 13 Dec 2017 Planned End Date changed from 1 Apr 2027 to 1 Apr 2022.